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Abstract Many studies suggested that cyclin-dependent kinase
inhibitor (CDKI) p21 acts as a universal inhibitor of cyclin/
CDK catalytic activity. This protein has also been shown to
be a component of active cyclin/CDK complexes. In addition,
it has recently been suggested that p21 serves as an assembly
factor in platelet-derived growth factor (PDGF)-stimulated vas-
cular smooth muscle cells (VSMC). However, little is known
concerning the molecular mechanisms by which PDGF induces
p21 gene expression in VSMC. In this report we demonstrate
that PDGF induces the p21 expression at both the mRNA and
protein levels. This increase in p21 gene expression was due to
activation of the p21 promoter by PDGF. Through both deletion
and mutation analysis of the p21 promoter, we de¢ned a 10-bp
sequence that is required for the activation of the p21 promoter
by PDGF. In addition, gel shift and supershift assays demon-
strated that this PDGF-responsive element binds speci¢cally to
the transcription factor Sp1. These results demonstrate that Sp1
mediates PDGF-induced p21 gene expression in VSMC. More-
over, immunoblot and immonoprecipitation analysis showed that
the level of hyperphosphorylated retinoblastoma protein (Rb) is
increased and the protein is physically associated with Sp1 in
PDGF-treated cells, indicating that phosphorylated Rb may
play a role in regulating Sp1 to activate p21 expression.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Cell cycle transitions are controlled by the action of the
cyclin-dependent kinases (CDKs) and their activating sub-
units, the cyclins [1^3]. Arterial vascular smooth muscle cells
(VSMC) are normally quiescent, proliferate at low indices
(6 0.05%), and stay in the G0/G1 phase of the cell cycle [4].
After vascular injury, VSMC are stimulated to divide in re-
sponse to mitogens, and they exit the G1 phase and enter the
S phase. Cyclin D-CDK4 and cyclin E-CDK2 predominantly
act sequentially during the G1/S transition and are required
for cell cycle progression in this period [5]. CDK activity is
tightly regulated by a combination of mechanisms, including
changes in the cyclin or CDK levels and phosphorylation at
positively and negatively regulating amino acid residues. The
kinase activity of these cyclins/CDK complexes can be nega-
tively regulated by CDK-inhibitory proteins, including p21
and p27 [5,6]. Most in vivo studies suggest that the inhibitory
e¡ect of p21 is largely exerted during the G1 phase of the cell
cycle, with preferential binding to CDK4- and CDK2-contain-
ing complexes, and that it either inhibits their kinase activities
or prevents their activation by CDK-activating kinase (CAK)
leading to G1 arrest [7]. In addition, the regulation of p21 is
largely dependent on the presence of functional p53, a tran-
scriptional regulator that mediates cell cycle arrest after DNA
damage and in senescence [8,9]. However, the expression of
p21 in a variety of tissues from p53 null mice suggests that it
is also regulated by a p53-independent mechanism [10]. Re-
cently, there has appeared data implicating p21 in positive
e¡ects on cyclin/CDK activation [11,12]. In addition, it has
been suggested that in Platelet-derived growth factor (PDGF)-
stimulated VSMC, p21 functions as an assembly factor for
cyclin D1/CDK4 but not cyclin E/CDK2 [13,14]. In a pre-
vious study in this laboratory, immunoblot analysis showed
that p21 protein is increased in response to tumor necrosis
factor-K stimulation in VSMC [15]. In this report, we inves-
tigate the mechanism of PDGF-induced transcriptional acti-
vation of p21. We show here that PDGF activates the p21
promoter by stimulating the transcription factor Sp1, which
binds adjacent to the TATA box of the p21 promoter. Fur-
thermore, we demonstrate that Sp1 is physically associated
with retinoblastoma protein (Rb) in PDGF-treated VSMC.
2. Materials and methods
2.1. Materials
PDGF-BB was obtained from RpD Systems. The polyclonal anti-
bodies to Sp1 and Rb were obtained from Santa Cruz.
2.2. Cell culture
Human aortic smooth muscle cells were purchased from Bio-Whit-
taker (San Diego, CA, USA) and cultured in smooth muscle cell
growth medium containing 10% fetal bovine serum, 2 ng/ml of human
basic ¢broblast growth factor, 0.5 ng/ml of human epidermal growth
factor, 50 Wg/ml of gentamicin, 50 Wl/ml of amphotericin B, and 5 Wg/
ml of bovine insulin.
2.3. Immunoblot
Growth-arrested VSMC were treated with PDGF for the speci¢ed
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time periods at 37‡C. Cell lysates were prepared, and immunoblotting
was performed as described previously [15].
2.4. RNA isolation and Northern blot analysis
Total RNA was isolated from cells grown in a 100-mm-diameter
dish to 80% con£uency using an Isogen RNA isolation kit (Nippon
gene), and 20 Wg of total RNA per lane was examined by Northern
blot analysis. The p21WAF1/Cip1 cDNA for a probe was obtained
from a pCEP-WAF1 plasmid (a kind gift from Dr. Bert Vogelstein)
by digesting with NotI. Northern blot analysis was performed by
following standard methods [16].
2.5. Creation of p21 promoter reporter constructs
The human p21waf1 promoter construct, WWW-luc (p21P), was a
gift from Dr. B. Vogelstein [17]. p21P v2.3 and p21P smav1 were
described by Datto et al. [18]. The construction procedures of p21P
93-S and its mutated constructs were also described in detail by Datto
et al. [18].
2.6. Transient transfection
Each plasmid was transfected into VSMC using the Superfect re-
agent (Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. To assess promoter activity, cells were collected and dis-
rupted by sonication in lysis bu¡er (25 mM Tris^phosphate, pH 7.8,
2 mM EDTA, 1% Triton X-100, and 10% glycerol). After centrifuga-
tion, aliquots of the supernatants were tested for luciferase activity
using the luciferase assay system (Promega, Madison, WI, USA) ac-
cording to the manufacturer’s instructions. Fire£y luciferase activities
were standardized for L-galactosidase activity.
2.7. Stable transfectants
VSMC were transfected with either p21P93-S or p21P93-S Mut#2,
together with the pSV2neo vector to provide a selection marker, using
the Superfect reagent (Qiagen) according to the manufacturer’s in-
structions. Stable cell clones were selected by adding 400 Wg/ml
G418 in culture medium. After two weeks of selection, G418-resistant
clones were isolated with cloning rings.
2.8. Electrophoretic mobility shift assays
Nuclear extracts were prepared essentially as previously described
[15]. Binding reactions (20 Wl) containing 2 Wg poly(dI-dC), 10 mM
HEPES, pH 7.9, 50 mM NaCl, 0.5 mM DTT, 2.5 mM EDTA, 7 mM
MgCl2, 4% glycerol, and 4^6 Wg nuclear extract were incubated on ice
for 30 min with 20 000 cpm of 32P-labelled oligonucleotide, corre-
sponding to the bases 371 through 386 in either the wild-type p21
promoter, the mutant promoter construct p21P93-S mut#2.2, or the
mutant p21P93-S mut#2.3 (71^86 wt, GGTCCCGCCTCCTTGA and
TCAAGGAGGCGGGACC; 71^86 mut#2.2, GGTCCCGGATCCT-
TGA and TCAAGGATCCGGGACC; 71^86 mut#2.3, GGTCCC-
GCCGGCTTGA and TCAAGCCGGCGGGACC). Complexes were
separated on 6% non-denaturing polyacrylamide gels. The gels were
subsequently dried and autoradiographed [15].
For Sp1 supershift assay, Sp1-speci¢c polyclonal antibody was
added to the binding reaction prior to the addition of radiolabeled
probe.
2.9. Immunoprecipitations
Nuclear extracts of cells were precleared with 30 Wl of 1:1 slurry of
protein G-Sepharose1-radioimmune precipitation assay bu¡er for 1 h
with bi-directional rotation at 4‡C. Ten Wl of Sp1 rabbit polyclonal
IgG (Santa Cruz Biotechnology) was incubated with the precleared
lysates overnight at 4‡C with gentle shaking. After isolation of im-
mune complexes with protein G-Sepharose, the pellets were washed
twice and resolubilized in loading bu¡er, boiled for 5 min, and sub-
jected to Western blot analysis.
3. Results and discussion
To determine whether PDGF a¡ects p21 expression in
VSMC, we measured, ¢rst, the levels of p21 protein and
mRNA expression in the absence and presence of PDGF. In
agreement with previous reports [13,14], PDGF treatment in-
duced p21 mRNA expression in a time-dependent manner as
determined by Northern blot analysis, and consequently in-
creased p21 protein levels (Fig. 1A,B). Because PDGF dras-
tically induced the p21 mRNA expression, we then investi-
gated whether PDGF could stimulate the activity of the p21
gene promoter in cells transiently transfected by WWP-Luc,
which contains the 2.4-kb 5P £anking region of the human p21
gene and includes the p53 binding site located at 2.3 kb,
driving the expression of a luciferase reporter gene. As shown
in Fig. 2A, the luciferase activity was increased by treatment
with 10 ng/ml PDGF. These results demonstrate that PDGF
induces the expressions of p21 protein and mRNA, and also
activates its promoter activity.
To identify the DNA elements activated by PDGF in the
p21 promoter, we determined the regions of the p21 promoter
responsible for the activation of p21 promoter by PDGF. To
this end, a series of progressive 5P promoter deletion mutants
of the p21 promoter were tested (Fig. 2B). Deletion mutant
p21pv2.3 which does not contain p53 binding sites (Fig. 2A),
exhibited a modestly reduced PDGF response but did not
change the extent of PDGF induction relative to basal or
PDGF-induced activity. This result indicated that PDGF is
capable of inducing p21 independently of the p53 pathway.
Further deletion up to 393 bp did not a¡ect the PDGF-in-
duced activity, although the basal activity of the promoter
diminished. However, the minimal promoter construct,
p21Psma v1, which contains only 61 bp proximal to the tran-
scriptional initiation site, repressed the PDGF-induced pro-
moter activity. Results from these experiments suggest that
PDGF induces the p21 promoter through a 333-bp region
between 393 and 361.
Fig. 1. Increased p21 expression and transcriptional activity in
VSMC after PDGF treatment. A: VSMC were incubated in the ab-
sence or presence of PDGF for various times and cellular lysates
were prepared and analyzed by immunoblotting using p21-speci¢c
antibody. Blotted membranes were reprobed with anti-GAPDH. B:
VSMC were plated in the absence or presence of PDGF for various
times and total RNA was extracted and analyzed by Northern blot-
ting. GAPDH was used as control.
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To further de¢ne the PDGF-responsive elements, we used a
panel of p21 promoters point-mutated between bases 393 and
344. The p21P93S mut#1, p21P93S mut#3, p21P93S mut#4,
and p21P93S mut#5 did not a¡ect the PDGF-induced p21
promoter activity compared with that of p21P93S although
some constructs reduced the basal levels of activities (Fig.
2B). However, p21P93S mut#2 had almost completely lost
the ability to be activated by PDGF. We next examined
whether the Sp1 binding site between 374 and 383 is in-
volved in the transcriptional activation by PDGF. To this
end, an additional mutant construct, p21P93S mut#2.2, was
created. The p21P93S mut#2.2 has a mutation of bases 378
and 379, from CC to AG (Fig. 2B). This mutant construct
signi¢cantly reduced both the ability of the promoter to be
induced by PDGF and the basal promoter activity. These
results were con¢rmed by establishing stable cell lines. In par-
allel with the transient assay, the cell lines expressing p21P93S
mut#2 lost both basal and PDGF-induced activity compared
with those of p21P93S-transfected cells (Fig. 2C). Taken to-
gether, these results demonstrate that the Sp1 site located
between 374 and 383 relative to the transcription start site
is the main PDGF-responsive element.
To determine if any proteins could be detected that specif-
ically interact with the PDGF-responsive element, electropho-
retic mobility shift assays were performed with the wild-type
PDGF-responsive element sequence and the mutant PDGF-
responsive elements created in p21P93S mut#2 and p21P93S
mut#2.2. Nuclear extracts were prepared from both PDGF-
treated and untreated VSMC. Gel shift assays performed with
these extracts and 32P-end-labeled double-stranded oligonu-
cleotide probe containing the PDGF-responsive element con-
sensus sequence between 374 and 383 sites revealed a speci¢c
band of retarded mobility (Fig. 3A). The binding of this re-
tarded protein could be competed away by an excess of un-
labeled PDGF-responsive element DNA (Fig. 3B). Oligonu-
cleotides mut#2 and mut#2.2 failed to bind with nuclear
factors derived from PDGF-stimulated VSMC (Fig. 3A).
These results indicate that the PDGF-mediated p21 expression
Fig. 2. Analysis of the p21 promoter. A: 5P deletion analysis of the p21 promoter in VSMC. VSMC were transfected with the indicated p21
promoter reporter constructs, incubated for 24 h with or without PDGF (10 ng/ml), and assayed for luciferase activity. The fold induction was
determined by comparing luciferase activity in transfected cells treated with PDGF (closed bar) and in transfected cells without PDGF (open
bar). B: Mutational analysis of the p21 promoter in response to PDGF on VSMC. VSMC transfected with the indicated constructs were incu-
bated with or without PDGF and then assayed for luciferase activity. The fold induction by PDGF (closed bar) relative to an untreated control
(open bar) is shown. The bars represent the average results of two separate transfections in three independent experiments. C: Analysis of
p21P93-S mut#2 in stably transfected cells. VSMC stably transfected with either p21P93-S or p21P93-S Mut#2 promoter fragment inserted into
a luciferase reporter plasmid were treated with PDGF. Luciferase activity of the cell lysates was measured. The bars represent the average re-
sults of two separate transfections in three independent experiments.
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is absolutely dependent on the presence of intact Sp1 binding
site within the p21 promoter region.
Sp1 is one member of a family of factors that binds to the
Sp1 DNA site. To elucidate whether the retarded bands rep-
resent the binding of Sp1, a supershift assay was performed by
preincubating the nuclear extracts with anti-Sp1 antibody
(Fig. 3B). In the presence of anti-Sp1 antibody, the formation
of speci¢c DNA^protein complex was almost completely ab-
rogated, and a supershift band appeared in PDGF-treated
VSMC. These results indicate that Sp1 may be responsible
for PDGF-activated transcription.
Changes in the binding of Sp1 after PDGF stimulation
could be due to changes in Sp1 abundance. We therefore
evaluated Sp1 protein abundance in quiescent versus PDGF-
treated cells. Immunoblot analysis of total cell protein extract
showed no di¡erence in Sp1 protein abundance after PDGF
stimulation (Fig. 4A). As is also shown, the relative abun-
dance of the bands corresponding to the 95- and 105-kDa
species of Sp1 is also unchanged after PDGF treatment.
The results indicate that there may be some preexisting factors
modulating p21 gene expression. Previous reports have shown
using transient transfection assays that Rb is able to regulate
transcription of c-fos, c-myc, and TGF-L1 promoters in either
a positive or negative manner, dependent on the cell type [19^
21]. The Rb control elements in these promoters have been
de¢ned and found to interact with Sp1 [19^21]. In this study,
we demonstrate that Sp1 is involved in PDGF-induced p21
gene expression. In order to determine the relationship be-
tween Rb and p21 in PDGF-treated cells, we investigated
the level and phosphorylation status of Rb. As shown in
Fig. 4A, hyperphosphorylated Rb increased in PDGF-treated
VSMC, indicating that phosphorylated Rb may play an im-
portant role in regulating Sp1 to activate p21 expression. To
investigate the possibility of a physical interaction between Rb
and Sp1, an immunoprecipitation assay was performed. Nu-
clear extracts were incubated with anti-Sp1 antibody in the
primary immunoprecipitation; then the washed immunopreci-
Fig. 3. Electrophoretic mobility shift assays. A: DNA probes corresponding to the bases 371 through 386 of the wild-type p21 promoter,
p21P93-S mut#2, or p21P93-S mut#2.2, were end-labeled and incubated with nuclear extracts from PDGF-treated and untreated VSMC. As-
says were performed in the presence or absence of a 100-fold excess of unlabeled DNA probe as a speci¢c competitor. B: Supershift analysis
of Sp1 site binding protein by anti-Sp1 antibody. Protein samples were prepared from VSMC after treatment with PDGF for 24 h. Polyclonal
antibody against Sp1 was added to the binding reaction and incubated for 20 min at room temperature before addition of a labelled DNA
probe corresponding to the bases 371 through 386 of the wild-type p21 promoter. Preimmune IgG was used as a control in lane 2, and lane
3 shows competition by unlabeled probe.
Fig. 4. Sp1 co-immunoprecipitates with Rb. A: Immunoblot analy-
sis of Sp1 and Rb protein. Total cell proteins were isolated from
quiescent or PDGF-treated cells and used for immunoblot analysis
as described in Section 2. The arrows labeled ‘Sp-1’ indicate bands
corresponding to the 95- and 105-kDa species of Sp1. pRb and
ppRb indicate underphosphorylated forms and hyperphosphorylated
forms of pRb, respectively. B: Immunoprecipitation using Sp1 anti-
body. Twenty Wg of cell nuclear extract was immunoprecipitated
with anti-Sp1 antibody. The washed immunoprecipitates were sub-
jected to immunoblot using anti-Sp1 or anti-Rb antibody.
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pitates were subjected to Western blotting using anti-Sp1 or
anti-Rb antibody. Fig. 4B revealed the increased formation of
a physical complex between Rb and Sp1 protein in PDGF-
treated VSMC compared with the control. Our data from
immunoblot and immunoprecipitation analysis indicate that
the two proteins, phosphorylated Rb and Sp1, form part of
the same complex and cooperatively may activate p21 expres-
sion, although dissection of potential regulatory interactions
between Rb and Sp1 binding sites after PDGF stimulation
will require additional investigation.
Collectively, our results demonstrate that PDGF induces
p21 expression through activating the transcription factor
Sp1 in VSMC. Moreover, we show here that phosphorylated
Rb may play a role in regulating Sp1 to activate p21 expres-
sion. While much work in the area of inhibition of VSMC
proliferation has been concentrated on the elements of the
MAPK/ERK and other cytoplasmic kinase cascades and their
inhibitors, these ¢ndings may have broad implications for our
understanding of the normal cell cycle and the subversion of
control pathways in VSMC. These studies represent the initial
steps toward de¢ning the signaling pathways involved in
PDGF-mediated transcriptional activation of p21 in VSMC
proliferation. We believe that a major importance of our work
lies in its relevance and potential applications to diseases in-
volving aberrant VSMC proliferation, such as atherosclerosis
and angioplasty restenosis.
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